端粒酶催化亚基hTERT在肿瘤治疗中的研究进展  

Progression and study of the catalytic subunit of human telomerase(hTERT) in tumor therapy

作　　者：沈瑛[1] 张永[2] 丁健[1] 

机构地区：[1]中国科学院上海药物研究所国家新药研究重点实验室肿瘤药理组,上海201203 [2]中国科学院研究生院,北京100049

出　　处：《中国癌症杂志》2006年第7期584-588,共5页China Oncology

基　　金：国家自然科学基金项目(编号:30271513和30500618)

摘　　要：人端粒酶催化亚基hTERT基因转录的从头激活是端粒酶活化的限速步骤,受到多种癌基因和抑癌基因产物的精密调控。构建hTERT启动子调控抗肿瘤基因的逆转录病毒载体,使抗肿瘤基因在端粒酶阳性的肿瘤细胞内定向表达,有望用于肿瘤基因治疗。本文首先简单介绍了hTERT蛋白的结构和表达调控机制,然后对其在肿瘤发生发展中的生物治疗的功能作一简要综述。The de novo transcription of hTERT gene represents a rate-limiting step in the activation of human telomerase. The expression of hTERT is strictly regulated with several oncogene products and tumor suppressor gene products in normal cells. The construction of a reverse-transcriptional virus vector that contains the promoter of hTERT without losing its specificity can dramatically augment the expressions of anticancer genes in telomerase-positive cancer cells, which prompts the use of an hTERT promoter for anticancer gene therapies. Firstly, we briefly introduce the structure and regulation of hTERT gene, and then we also review the present knowledge of its biological function in cancer progression.

关 键 词：端粒酶 人端粒酶催化亚基 肿瘤 基因治疗 

分 类 号：R730.5[医药卫生—肿瘤]